Surgery – Diagnostic testing – Sampling nonliquid body material
Reexamination Certificate
2002-01-30
2004-04-06
Marmor, Charles (Department: 3736)
Surgery
Diagnostic testing
Sampling nonliquid body material
C600S562000, C600S431000, C606S041000, C606S045000
Reexamination Certificate
active
06716179
ABSTRACT:
BACKGROUND OF THE INVENTION
The invention relates to the field of medical devices and methods used in the treatment of diseases such as cancer which have the ability to metastasize within a patient's body. More specifically, the invention is directed to methods and devices for locating sentinel lymph nodes associated with a lesion site within a patient's body so that the sentinel lymph nodes may thereafter be selectively removed and analyzed to determine whether disease has spread from the primary lesion site to the sentinel lymph nodes. In the case of breast cancer patients, such methods and devices may eliminate the need for complete axillary lymph node dissection in patients who do not require such invasive and debilitating procedures.
With regard to breast cancer patients specifically, the determination of the severity of the disease or staging is frequently determined by the level of lymph node involvement in those lymph nodes which correspond to the primary cancer lesion site in the breast. The lymph nodes which correspond to the breast area are typically located in the armpit or axilla of the patient and are connected to the breast tissue of the patient by a series of lymph ducts. Other likely areas for sentinel nodes include inframammary and submammary locations and elsewhere in the patient's chest. The sentinel lymph nodes can be in fluid communication with other surrounding lymph nodes, however, lymph drainage from the lesion site will first flow to the sentinel lymph nodes. Thereafter, lymph fluid drainage may then continue on to lymph nodes surrounding the sentinel nodes.
Studies have shown that by the time a typical breast cancer lesion reaches the size of 1-2 cm, the cancer will have metastasized to at least one of the sentinel lymph nodes in about one third of patients. Malignant cells break off and drain through the lymph fluid ducts to the lymph nodes and will be apparent in excised lymph nodes if the malignant cells embed in the lymph node. In patients with more advanced disease, the likelihood of spread to sentinel nodes is higher as is the likelihood of spread of the disease to the lymph nodes surrounding the sentinel lymph nodes.
As discussed above, when a tumor lesion is under 1-2 cm, only about ⅓ of patients will have cancer cells in the corresponding lymph nodes, and in the patients where the disease has spread to the lymph nodes, it is often confined to the sentinel lymph nodes.
In the past, a breast cancer patient would normally have a complete axillary lymph node dissection as an adjunct to removal of the primary lesion in the breast. Thus, the patient's entire lymph node system in the armpit area is removed and biopsied to determine the stage of the cancer and what further treatment was required. However, as discussed above, when the lesion is under 1-2 cm, two thirds of the patients had no migration of cancer cells to the lymph nodes at all, and in others, cancer had only migrated to the sentinel lymph nodes. Thus, total axillary lymph node dissection in two-thirds of the cases were unnecessary. It should be noted that total axillary lymph node dissection can be an extremely painful and debilitating procedure for patients who often suffer from severe lymph edema as a result of the body's inability to channel the flow of lymph fluid once most or all of the lymph nodes have been excised.
Thus there is a need for methods and devices that can be used to determine the location of sentinel lymph nodes corresponding to a patient's primary lesion site, and a reliable and noninvasive means of accessing the sentinel lymph nodes to determine whether they are involved in the disease. If the sentinel lymph nodes are determined not to have cancer cells within them, then a total axillary lymph node dissection may be avoided.
It has been known to use radioactive materials or radiopharmaceuticals as localizing agents which can be injected into the area of a primary lesion to monitor the flow of the materials within the patients body using a variety of detectors. Radioactive material such as Technetium 99 m, Indium 111, Iodine 123 or Iodine 125 can be injected in a fluid into the site of a primary lesion and the migration of the radioactive material through lymph ducts to the patient's corresponding sentinel lymph nodes and other surrounding lymph nodes monitored. Although techniques exist to locate the sentinel lymph nodes of a patient with such radiopharmaceutical tagging, what has been needed are methods and devices to precisely locate and access the sentinel lymph nodes of the patient in a noninvasive manner so as to minimize trauma to the patient should it be determined that a total axillary node dissection is unnecessary.
SUMMARY OF THE INVENTION
The invention is directed generally to a method and system for locating and/or accessing specific target sites within the body of a patient. More specifically, the invention is directed to a method and system for locating and accessing a sentinel lymph node of a patient which corresponds to a lesion site within the patient's body.
In one embodiment of the invention, a radioactive material is injected into a patient's body near a primary lesion site or other site of interest within the patient. The approximate position of a sentinel lymph node is within the patient's body is determined by detecting radiation from the radioactive material accumulated within the sentinel lymph node with a radiation detector external to the patient's body. The sentinel lymph node can then be accessed with a cannula having an RF electrode disposed on a distal end of the cannula by activating the RF electrode to ablate tissue while passing the cannula into the patient's body until the distal end of the cannula is disposed adjacent the sentinel lymph node. Thus, access to a patient's sentinel lymph node corresponding to a lesion site is achieved with minimal trauma to the patient, requiring only a hypodermic injection at the lesion site and a channel through the patient's tissue from the outside surface of the skin to the sentinel node, the channel being no larger than the outside dimension of the cannula.
Once the distal end of the cannula is positioned adjacent the sentinel lymph node, an anchor device can be inserted through the cannula and into the sentinel lymph node. The distal end of the anchor device can then be secured to the sentinel lymph node. Once the distal end of the anchor device is secured to the lymph node, the patient can be transferred to a surgical suite and the lymph node surgically removed with the anchor device attached thereto. The anchor device is thus used as a locator for the sentinel lymph node during the surgical procedure.
In some embodiments of a method of the invention, a gamma camera is used to determine the approximate position of the sentinel lymph node within the patient's body prior to accessing the sentinel lymph node with the cannula assembly. Alternatively, a hand held radiation detecting wand or the like can be used to determine the approximate position of the sentinel lymph node within the patient's body. Once the approximate position of a sentinel lymph node is known, the skin of the patient can be marked with a visible mark above the location of the sentinel lymph node prior to accessing the sentinel lymph node with the cannula.
A cannula suitable for use with the method discussed above can have an outer hollow shaft having an inner lumen slidingly disposed about an inner shaft having an RF electrode disposed on the distal end of the inner shaft. The inner shaft can be withdrawn from the outer hollow shaft prior to insertion of the anchor device through the inner lumen of the outer hollow shaft to access a sentinel lymph node. The RF electrode can be an arcuate shaped wire spaced distally from a distal extremity of the distal end of the cannula whereby tissue is ablated along the length of the RF electrode and displaced by the distal end of the cannula as it is advanced through the tissue. Often it is desirable
Burbank Fred H.
Lubock Paul
Duane Morris LLP
Lynch Edward J.
Marmor Charles
Senorx, Inc.
LandOfFree
Sentinel node location and biopsy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sentinel node location and biopsy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sentinel node location and biopsy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3228044